| Literature DB >> 27465043 |
C Lavaud1,2, M Baviere1, G Le Roy1,2, M R Hervé1, A Moussart2,3, R Delourme1, M-L Pilet-Nayel4,5.
Abstract
BACKGROUND: Understanding the effects of resistance QTL on pathogen development cycle is an important issue for the creation of QTL combination strategies to durably increase disease resistance in plants. The oomycete pathogen Aphanomyces euteiches, causing root rot disease, is one of the major factors limiting the pea crop in the main producing countries. No commercial resistant varieties are currently available in Europe. Resistance alleles at seven main QTL were recently identified and introgressed into pea agronomic lines, resulting in the creation of Near Isogenic Lines (NILs) at the QTL. This study aimed to determine the effect of main A. euteiches resistance QTL in NILs on different steps of the pathogen life cycle.Entities:
Keywords: Near Isogenic Lines (NILs); Partial resistance; Pisum sativum; Q-PCR; Quantitative Trait Loci (QTL); Root colonization speed; Root rot; Symptom appearance
Mesh:
Year: 2016 PMID: 27465043 PMCID: PMC4964060 DOI: 10.1186/s12870-016-0822-4
Source DB: PubMed Journal: BMC Plant Biol ISSN: 1471-2229 Impact factor: 4.215
Description of the NILs and controls used
| NILa | Donor lineb | Recipient linec | Generation | Introgressed QTLd | Experiment |
|---|---|---|---|---|---|
| 0-QTL | |||||
| NIL1-0b | RIL 831.08 | Puget | BC5F3 | - | 2 |
| NIL4-0b | RIL 847.50 | DSP | BC5F3 | - | 1,3 |
| NIL7-0b | RIL BAP8.70 | Baccara | BC5F3 | - | 1,4 |
| Single-QTL | |||||
| NIL1-4.5b | RIL 831.08 | Puget | BC5F3 |
| 2 |
| NIL4-5.1a | RIL 847.50 | DSP | BC5F3 |
| 3 |
| NIL4-5.1b | RIL 847.50 | DSP | BC5F3 |
| 1 |
| NIL4-7.6a | RIL 847.50 | DSP | BC5F3 |
| 1,3 |
| NIL7-4.1a | RIL BAP8.70 | Baccara | BC5F3 |
| 1 |
| NIL7-7.6a | RIL BAP8.70 | Baccara | BC5F3 |
| 1 |
| NIL10-1.2a | RIL BAP8.195 | Baccara | BC5F3/4 |
| 1 |
| NIL10-2.2c | RIL BAP8.195 | Baccara | BC5F3 |
| 1 |
| NIL10-3.1b | RIL BAP8.195 | Baccara | BC5F3 |
| 1 |
| NIL13-2.2a | 552 | Baccara | BC6F4 |
| 1,4 |
| NIL13-3.1a | 552 | Baccara | BC6F3/4 |
| 1,4 |
| NIL13-7.6b | 552 | Baccara | BC6F4 |
| 1,4 |
| QTL combination | |||||
| NIL4-5.1/7.6a | RIL 847.50 | DSP | BC5F3 |
| 3 |
| NIL4-5.1/7.6b | RIL 847.50 | DSP | BC5F3/4 |
| 3 |
| NIL13-2.2/7.6a | 552 | Baccara | BC6F3 |
| 4 |
| NIL13-2.2/7.6b | 552 | Baccara | BC6F3 |
| 4 |
| NIL13-3.1/7.6a | 552 | Baccara | BC6F4 |
| 4 |
| NIL13-3.1/7.6b | 552 | Baccara | BC6F4 |
| 4 |
| NIL13-2.2/3.1/7.6a | 552 | Baccara | BC6F3 |
| 4 |
| NIL13-2.2/3.1/7.6b | 552 | Baccara | BC6F4 |
| 4 |
| Control lines | |||||
| 90-2131 | - | - | - | - | 1,3 |
| PI180693 | - | - | - | - | 1 |
| 552 | - | - | - | - | 1,4 |
| RIL831.08 | - | - | - | - | 2 |
| RIL847.50 | - | - | - | - | 3 |
NILs carrying resistance alleles at zero, one, two or three of the seven A. euteiches resistance QTL in pea [25]
aNILs are coded as follow: NIL“NIL set number”-“0 for zero QTL or QTL number(s)” “sister NIL letter (a or b)” [25]. bLines used as donors of resistance alleles at one to three QTL in the Marker-Assisted Backcrossing (MAB) scheme [25]. cSusceptible parents of the RIL populations in which the QTL were detected, used as reference recipient parents in the MAB scheme [19]. dQTL introgressed from the donor lines in the MAB scheme [25]
Disease Severity lsmeans scores in single-QTL NIL experiments
| Experiment | Crossa | Genotype | QTLb | Day after inoculationc | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (Strain) | 2d | 3d | 4e | 5 | 6 | 7 | 10 | |||
| 1 | DSP * RIL 847.50 | NIL4-0b |
| NA | NA | 2,0 | −1,6 | −2,3 | −4,1 | −3,3 |
| (RB84) | NIL4-5.1b |
| NA | NA | 3,9* | −0,5 | −1,0 | −3,7 | −2,4 | |
| NIL4-7.6a |
| NA | NA | 4,1* | 1,7*** | 0,4*** | −0,8*** | −0,6*** | ||
| 90-2131 |
| NA | NA | 3,1 | −1,3 | −1,1 | −4,2 | −2,9 | ||
| Baccara * RIL BAP8.70 | NIL7-0b |
| NA | NA | 2,6 | −2,5 | −3,7 | −1,0 | −1,9 | |
| NIL7-4.1a |
| NA | NA | 2,0 | −2,6 | −3,7 | −0,7 | −2,2 | ||
| NIL7-7.6a |
| NA | NA | 4,0 | 1,6*** | −0,1*** | 1,4** | 0,2** | ||
| PI180693 |
| NA | NA | 4,5 | 1,4*** | 0,9*** | 3,0*** | 2,3*** | ||
| Baccara * RIL BAP8.195 | NIL7-0b |
| NA | NA | 0,8 | −2,4 | −3,2 | −1,0 | −2,3 | |
| NIL10-1.2a |
| NA | NA | 1,3 | −1,4 | −2,8 | −1,6 | −3,2 | ||
| NIL10-2.2c |
| NA | NA | 0,7 | −2,6 | −2,5 | −0,5 | −1,9 | ||
| NIL10-3.1b |
| NA | NA | 1,1 | −2,4 | −3,0 | −0,8 | −2,3 | ||
| PI180693 |
| NA | NA | 2,6 | 1,3*** | 0,7*** | 2,8*** | 2,5*** | ||
| Baccara * 552 | NIL7-0b |
| NA | NA | 0,8 | −1,9 | −3,9 | −1,7 | −2,9 | |
| NIL13-2.2a |
| NA | NA | 0,5 | −1,2 | −2,7 | −1,9 | −3,4 | ||
| NIL13-3.1a |
| NA | NA | 2,6 | −1,1 | −2,8 | −1,1 | −1,9 | ||
| NIL13-7.6b |
| NA | NA | 1,9 | 0,1* | −0,3*** | −0,3 | −2,2 | ||
| 552 |
| NA | NA | 2,6 | 1,2*** | 0,4*** | 0,6** | 0,0** | ||
| 2 | Puget * RIL 831.08 | NIL1-0b |
| NA | NA | 1,6 | 1,6 | −0,9*** | −2,2 | −2,7 |
| (Ae109) | NIL1-4.5b |
| NA | NA | 3,6 | 2,5 | 2,1 | 1,4*** | 1,2*** | |
| RIL 831.08 |
| NA | NA | 3,7 | 4,8*** | 2,6*** | 1,6 | 1,6*** | ||
a“Recipient x donor” cross lines from which each NIL was produced in the previous MAB scheme [25]. bQTL introgressed in each NIL from the previous MAB scheme [25]. cLSMeans disease severity (DS) scores obtained on each genotype and scoring day from the CLMM analysis of each NIL set in experiments #1 and #2. Lsmeans scores were obtained from the DS score probabilities for each genotype and scoring day represented in Additional file 1A. LSMeans DS values ranged from −4.2 to 4.8, according to the scale of the latent variable implied by the CLMM. Significant differences between LSMeans values of the single-QTL NILs or the resistant control, and the control-NIL without QTL are indicated by *(0.01 < P < 0.05), **(0.001 < P < 0.01) and ***(P < 0.001). dAt two and three days after inoculation, LSMeans DS scores could not be estimated from CLMM since some lines did not have symptoms. eAt four days after inoculation, LSMeans DS scores were estimated from data obtained in one biological replicate in experiment #2
A. euteiches DNA amounts in roots in single-QTL NIL experiments
| Experiment (Strain) | Crossa | Genotype | QTLb | Day after inoculationc | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 3 | 4d | 5 | 6 | 7 | 10 | ||||
| 1 | DSP * RIL 847.50 | NIL4-0b |
| NA | 3,0 ± 0,5 | 44,9 ± 4,3 | 201,8 ± 21,7 | 387,0 ± 35,0 | 576,8 ± 46,8 | 1110,8 ± 69,2 |
| (RB84) | NIL4-5.1b |
| NA | 2,5 ± 0,5 | 11,2 ± 4,3*** | 117,8 ± 21,7*** | 325,4 ± 33,5* | 425,7 ± 45,7*** | 839,4 ± 69,2*** | |
| NIL4-7.6a |
| NA | 2,0 ± 0,5 | 15,5 ± 4,3*** | 81,6 ± 22,6*** | 155,4 ± 35,0*** | 351,9 ± 45,3*** | 699,5 ± 70,6*** | ||
| 90-2131 |
| NA | 5,3 ± 0,4 | 31,6 ± 4,3* | 162,0 ± 21,7* | 297,7 ± 34,8** | 348,5 ± 45,3*** | 858,8 ± 69,2** | ||
| Baccara * RIL BAP8.70 | NIL7-0b |
| NA | 5,3 ± 0,3 | 43,9 ± 4,0 | 294,9 ± 16,6 | 523,2 ± 17,1 | 679,7 ± 29,1 | 1721,5 ± 80,9 | |
| NIL7-4.1a |
| NA | 6,0 ± 0,3 | 67,4 ± 4,0 | 260,0 ± 16,6 | 421,9 ± 17,1** | 650,2 ± 29,1 | 1478,2 ± 80,9 | ||
| NIL7-7.6a |
| NA | 1,6 ± 0,6*** | 17,0 ± 4,0*** | 58,8 ± 16,6*** | 251,0 ± 17,1*** | 437,4 ± 26,1*** | 882,4 ± 80,9*** | ||
| PI180693 |
| NA | 2,0 ± 0,5*** | 17,3 ± 4,0*** | 53,7 ± 16,6*** | 81,6 ± 26,4*** | 167,5 ± 26,1*** | 401,7 ± 80,9*** | ||
| Baccara * RIL BAP8.195 | NIL7-0b |
| NA | 5,3 ± 0,8 | 43,9 ± 12,3 | 294,9 ± 22,5 | 523,2 ± 23,8 | 652,1 ± 73,9 | 1721,5 ± 127,2 | |
| NIL10-1.2a |
| NA | 4,4 ± 0,8 | 43,3 ± 12,3 | 180,9 ± 22,5*** | 362,0 ± 23,8*** | 827,9 ± 67,0 | 1450,7 ± 127,2 | ||
| NIL10-2.2c |
| NA | 3,3 ± 0,9* | 48,1 ± 12,3 | 229,4 ± 22,5** | 407,7 ± 23,8** | 527,7 ± 73,9 | 1360,2 ± 127,2* | ||
| NIL10-3.1b |
| NA | 5,6 ± 0,8 | 47,8 ± 12,3 | 177,5 ± 22,5*** | 377,2 ± 27,6*** | 652,5 ± 73,9 | 1478,4 ± 127,2 | ||
| PI180693 |
| NA | 0,9 ± 1,0*** | 17,3 ± 12,3*** | 53,7 ± 22,5*** | 88,1 ± 33,8*** | 167,5 ± 67,0*** | 401,7 ± 127,2*** | ||
| Baccara * 552 | NIL7-0b |
| NA | 5,3 ± 0,6 | 43,9 ± 7,0 | 294,9 ± 19,6 | 523,2 ± 21,4 | 694,8 ± 36,6 | 1721,5 ± 116,2 | |
| NIL13-2.2a |
| NA | 6,0 ± 0,6 | 77,5 ± 7,0 | 186,8 ± 21,5*** | 344,9 ± 21,4*** | 549,2 ± 32,9** | 1117,6 ± 143,0** | ||
| NIL13-3.1a |
| NA | 5,1 ± 0,6 | 43,7 ± 7,0 | 168,4 ± 19,6*** | 247,7 ± 21,4*** | 451,5 ± 32,9*** | 991,5 ± 116,2*** | ||
| NIL13-7.6b |
| NA | 1,7 ± 0,6*** | 19,9 ± 7,0* | 76,9 ± 19,6*** | 178,9 ± 29,7*** | 341,5 ± 38,1*** | 681,7 ± 116,2*** | ||
| 552 |
| NA | NA | 4,2 ± 8,3*** | 14,0 ± 19,6*** | 82,8 ± 21,4*** | 177,0 ± 32,9*** | 428,6 ± 116,2*** | ||
| 2 | Puget * RIL 831 .08 | NIL1-0b |
| NA | 2,6 ± 0,4 | 32,6 ± 7,7 | 91,8 ± 26,3 | 293,5 ± 7,9 | 535,0 ± 35,0 | 1349,9 ± 158,7 |
| (Ae109) | NIL1-4.5b |
| NA | NA | NA | NA | 7,3 ± 7,6*** | 27,8 ± 35,0*** | 88,2 ± 158,7*** | |
| RIL 831.08 |
| NA | NA | NA | 30,6 ± 27,1** | 26,4 ± 9,1*** | 92,1 ± 39,6*** | 304,5 ± 166,6*** | ||
a“Recipient x donor” cross lines from which each NIL was produced in the previous MAB scheme [25]. bQTL introgressed in each NIL from the previous MAB scheme [25]. cPathogen DNA amount were obtained on each genotype and scoring day from the LMM analysis of each set of lines in experiments #1 and #2. LSMeans and standard errors of pathogen DNA amount are presented in thousand DNA copies (10^3). In each set of lines, significant differences of LSMeans DNA amount between the single-QTL NILs or the resistant control, and the control- NIL without QTL are indicated by *(0.01 < P < 0.05), **(0.001 < P < 0.01) and ***(P < 0.001). dIn experiments #1 and #2, LSMeans DNA amount were estimated from data obtained in one biological replicate at the fourth day. NA: Not Available data due to copy number <103
Fig. 1Effects of NILs carrying single or combined resistance QTL Ae-Ps5.1 and Ae-Ps7.6 on variables of Aphanomyces root rot development cycle. a/ Single QTL NIL experiment #1; b/ Combined and single QTL NIL experiment #3. The first graph represents the evolution of the probability of symptom appearance for seven days after inoculation, for each line. It corresponds to the percentage of plants with symptoms per block for each scoring day. The second graph shows for each line the root colonization speed, corresponding to the slope of the curve of pathogen DNA amounts per block, until 10 days after inoculation, from 104 DNA copies detected. Pathogen DNA data were used from one biological replicate at the fourth day in experiment #1 and the tenth day in experiment #3. In the third graph, the AUDPC was calculated from the pathogen DNA quantification data over the ten days after inoculation. Bars represent standard errors. Attribution of each line to LSMeans group(s) is indicated by letter(s), according to the Tukey test (P < 0.05). Blue and red lines indicate the NIL without QTL and the donor or resistant control lines, respectively
Disease Severity lsmeans scores and A. euteiches DNA amounts in roots, in multiple-QTL NIL experiments
| Experiment (Strain) | Crossa | Genotype | QTLb | Symptom scoringc |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day after inoculation | Day after inoculation | ||||||||||||||||
| 2d | 3d | 4f | 5 | 6 | 7 | 10 | 2 | 3 | 4 | 5 | 6 | 7f | 10f | ||||
|
|
| NIL4-0b | - | NA | NA | −1.6 | −2.9 | −1.2 | −4.6 | −5.0 | NA | 23.8 ± 2.5 | 226.5 ± 14.1 | 522.6 ± 23.8 | 696.1 ± 36.8 | 817.6 ± 41.7 | 1142.9 ± 59.4 |
|
| NIL4-5.1a |
| NA | NA | −0.7 | −1.5 | −0.1 | −2.4*** | −4.6 | NA | 18.1 ± 2.5 | 131.8 ± 14.1*** | 368 ± 21.3*** | 558.4 ± 33.8** | 668.1 ± 35.1* | 871.7 ± 59.4*** | |
| NIL4-7.6ag |
| NA | NA | 0.5* | 0.0*** | 1.0** | −1.5 | −3.8 | NA | 11.9 ± 3.1** | 98.1 ± 17.2*** | 339.3 ± 28.1*** | 561.8 ± 42* | 633.1 ± 41.7* | 855.8 ± 71.8*** | ||
| NIL4-5.1/7.6a |
| NA | NA | 1.9*** | 0.9*** |
|
|
| NA | 7 ± 2.5*** | 73.8 ± 15.2*** |
|
| 477.9 ± 31.5*** | 826.2 ± 59.4*** | ||
| NIL4-5.1/7.6b |
| NA | NA | 1.2*** | 0.8*** |
|
| −1.4** | NA | 9.1 ± 2.5*** | 71.1 ± 14.1*** |
|
| 495.1 ± 31.5*** | 739.1 ± 59.4*** | ||
| 90-2131 | - | NA | NA | −0.3 | −1.7 | −0.8 | −3.3 | −4.3 | NA | 15.3 ± 2.5* | 101.5 ± 14.1*** | 279.4 ± 21.3*** | 533.8 ± 33.8*** | 675.2 ± 35.4 | 911 ± 59.4*** | ||
| RIL 847.50 | - | NA | NA | 1.2*** | 1.0*** | 2.5*** | −0.2*** | −2.0* | NA | 7.6 ± 2.5*** |
|
| NA |
| 758.3 ± 59.4*** | ||
|
|
| NIL7-0b | - | NA | NA | 0.6 | 2.0 | 2.8 | 5.0 | 2.7 | 1.3 ± 0.3 | 6.9 ± 0.9 | 70.5 ± 7.9 | 295.3 ± 38.3 | 634.7 ± 52.9 | 806.1 ± 56.1 | 1948 ± 156.1 |
|
| NIL13-2.2a |
| NA | NA | −0.9 | 0.9 | 2.3 | 4.5 | 2.0 | 1.6 ± 0.2 | 12.3 ± 0.9 | 86.7 ± 7.7 | 309 ± 36 | 798.5 ± 50.3 | 970.4 ± 64.3 | 2095.5 ± 156.1 | |
| NIL13-3.1a |
| NA | NA | −1.3* | 0.1* | 1.0 | 3.2 | 1.7 | 3.6 ± 0.6 | 6 ± 1.1 | 42.5 ± 7.7* | 270 ± 35.5 | 455.6 ± 43.8 | 761.6 ± 56.1 | 1384.5 ± 167.9 | ||
| NIL13-7.6b |
| NA | NA | −2.0*** | −0.4*** | 1.4 | 2.9* | 3.1 | NA | 3.3 ± 1.3*** | 28.9 ± 7.7*** | 239.1 ± 35.5 | 476.2 ± 53 | 709.9 ± 56.1 | 1544.2 ± 156.1 | ||
| NIL13-2.2/7.6a |
| NA | NA | −1.2** | 0.6 | 1.4 | 3.1 | 3.0 | NA | 4.7 ± 0.9 | 55.8 ± 7.9 | 314.6 ± 35.5 | 566.9 ± 45.5 | 805.5 ± 64.3 | 1573.8 ± 156.1 | ||
| NIL13-2.2/7.6b |
| NA | NA | −1.1 | 0.7 | 1.8 | 3.5 | 2.0 | NA | 6.8 ± 0.9 | 66.3 ± 7.9 | 346.7 ± 37.4 | 651.1 ± 43.8 | 901.2 ± 58.3 | 1416.7 ± 167.9 | ||
| NIL13-3.1/7.6a |
| NA | NA | −1.8 | −0.8*** | 0.8 | 2.3** | 1.5 | 1.1 ± 0.7 | 3 ± 1*** | 35.7 ± 7.9** | 166.5 ± 36** | 431.1 ± 45.5** | 694.5 ± 56.1 | 1254.7 ± 156.1** | ||
| NIL13-3.1/7.6b |
| NA | NA | −2.1 | −0.4** | 0.9 | 2.4** | 2.5 | 1.1 ± 0.6 | 3.4 ± 0.9 | 46.7 ± 7.9* | 259.3 ± 35.5 | 494 ± 43.8 | 680 ± 56.1 | 1522 ± 156.1 | ||
| NIL13-2.2/3.1/7.6a |
| NA | NA | −2.0*** | −0.8*** | 0.9 | 2.8* | 0.9 | 1.1 ± 0.7 | 3.1 ± 1.1** | 30.9 ± 7.7*** | 181.8 ± 36* | 428.4 ± 43.8* | 576.2 ± 64.3* | 1231 ± 156.1** | ||
| NIL13-2.2/3.1/7.6b |
| NA | NA | −1.2** | −0.1* | 0.6 | 3.0 | 2.9 | NA | 3.8 ± 0.9** | 42.3 ± 7.7* | 221.4 ± 36 | 403.7 ± 43.8** | 646.9 ± 64.3 | 1258.8 ± 161.6* | ||
| 552 | - | NA | NA | −2.9*** |
|
|
|
| NA | 1.1 ± 1.5*** | 3.7 ± 8.5*** |
|
|
|
| ||
a“Recipient x donor” cross lines from which each NIL was produced in the previous MAB scheme [25]. bQTL introgressed in each NIL from the previous MAB scheme [25]. cLSMeans disease severity (DS) scores obtained on each genotype and scoring day from the CLMM analysis of each NIL set in experiments #3 and #4. Lsmeans scores were obtained from the DS score probabilities for each genotype and scoring day represented in Additional file 1B. LSMeans DS values ranged from −5 to 5, according to the scale of the latent variable implied by the CLMM. Significant differences between LSMeans values of the single-QTL NILs or the resistant control, and the control-NIL without QTL are indicated by *(0.01 < P < 0.05), **(0.001 < P < 0.01) and ***(P < 0.001). dAt two and three days after inoculation, LSMeans DS scores could not be estimated from CLMM since some lines did not have symptoms. ePathogen DNA amount were obtained on each genotype and scoring day from the LMM analysis of each NILs set in experiments #3 and #4. LSMeans and standard errors of pathogen DNA amount are presented in thousand DNA copies (10^3). In each set of lines, significant differences of LSMeans DNA amount between the single-QTL NILs or the resistant control, and the control- NIL without QTL are indicated by *(0.01 < P < 0.05), **(0.001 < P < 0.01) and ***(P < 0.001). fLSMeans scores were estimated from data in one biological replicate, for DS scoring at the fourth day in experiment #3 and #4 and for pathogen DNA data at the tenth day in experiment #3 and the seventh day in experiment #4. gLSMeans DS scores and pathogen DNA amounts for NIL4-7.6a were estimated from data in one biological replicate at all days. NA: Not Available data due to copy number <103 or to inconsistent data. In bold, significant differences of LSMeans DS scores or DNA amounts between the multiple-QTL NILs and the single-QTL NIL NIL4-7.6a for experiment #3 or NIL13-7.6b for experiment #4 (P < 0.05)